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Background: COPD exacerbations are associated with neutrophilic airway inflammation. Adhesion molecules on
the surface of neutrophils may play a key role in their movement from blood to the airways. We analysed adhesion
molecule expression on blood and sputum neutrophils from COPD subjects and non-obstructed smokers during
experimental rhinovirus infections.
Methods: Blood and sputum were collected from 9 COPD subjects and 10 smoking and age-matched control
subjects at baseline, and neutrophil expression of the adhesion molecules and activation markers measured using
flow cytometry. The markers examined were CD62L and CD162 (mediating initial steps of neutrophil rolling and
capture), CD11a and CD11b (required for firm neutrophil adhesion), CD31 and CD54 (involved in neutrophil
transmigration through the endothelial monolayer) and CD63 and CD66b (neutrophil activation markers). Subjects
were then experimentally infected with rhinovirus-16 and repeat samples collected for neutrophil analysis at
post-infection time points.
Results: At baseline there were no differences in adhesion molecule expression between the COPD and non-COPD
subjects. Expression of CD11a, CD31, CD62L and CD162 was reduced on sputum neutrophils compared to blood
neutrophils. Following rhinovirus infection expression of CD11a expression on blood neutrophils was significantly
reduced in both subject groups. CD11b, CD62L and CD162 expression was significantly reduced only in the COPD
subjects. Blood neutrophil CD11b expression correlated inversely with inflammatory markers and symptom scores in
COPD subjects.
Conclusion: Following rhinovirus infection neutrophils with higher surface expression of adhesion molecules are
likely preferentially recruited to the lungs. CD11b may be a key molecule involved in neutrophil trafficking in COPD
exacerbations.
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Chronic obstructive pulmonary disease (COPD) is a
growing global epidemic and its prevalence is expected
to increase markedly in the future [1]. The major cause
of morbidity and mortality in COPD are acute exacerba-
tions that are associated with impaired quality of life,
accelerated loss of lung function and enormous health
care costs [2]. The main causes of exacerbations are
viral and bacterial infections [3,4]. Acute exacerbations* Correspondence: s.johnston@imperial.ac.uk
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reproduction in any medium, provided the orare associated with increased airways inflammation with
an influx of inflammatory cells such as neutrophils into
the airways [3,4] and this inflammatory response is be-
lieved to be central to the pathogenesis of exacerbations.
Neutrophil migration from the blood is a tightly controlled
process that involves interactions between adhesion mole-
cules on neutrophils and their ligands on endothelial cells.
Initial selectin-mediated rolling is followed by integrin-
dependent firm adhesion and transendothelial migration.
The selectins CD62L (L-selectin) and CD162 (P-selectin
glycoprotein ligand-1) mediate the initial steps of rolling
and capture, firm adhesion requires the integrins CD11a
(lymphocyte function-associated antigen-1) and CD11btd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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through the endothelial monolayer involves CD31 (plate-
let endothelial cell adhesion molecule-1) [5]. Other mole-
cules including CD54 (intercellular adhesion molecule-1
(ICAM-1)) are also involved in neutrophil transmigration
but their exact role is undetermined. In addition neutro-
phils express a number of activation molecules including
CD63 and CD66b that are expressed on the cell surface
upon activation and degranulation of neutrophils. The
role of specific adhesion molecules in neutrophil recruit-
ment in vivo in COPD has not been established. Neu-
trophilic inflammation in COPD is poorly responsive to
corticosteroids, so different anti-inflammatory approaches
are needed and inhibition of adhesion molecules is one
such approach that merits exploration [6].
We have previously reported increases in sputum
neutrophils in COPD subjects following experimental
rhinovirus infection [4]. In the present study we analysed
expression of adhesion molecules and activation markers
on neutrophils in blood and sputum during experimen-
tal rhinovirus infection in COPD subjects and a control
group of smokers with normal lung function.
Methods
Study participants
Subjects were recruited from Imperial College Healthcare
NHS Trust (St Mary’s Hospital), the Royal Brompton Hos-
pital, local General Practices and by advertisement. Ethical
approval was obtained from StMary’s Local Research Ethics
Committee (study number 00/BA/459E). Two subject
groups were recruited for this study – a group of COPD
subjects (GOLD stage II) and a group of smokers with nor-
mal lung function. All subjects were aged between 40–75
years, non-atopic, were current or ex-smokers with at least
20 pack years cumulative smoking, had no symptoms of re-
spiratory tract infection within the previous 8 weeks and no
treatment with oral or inhaled corticosteroids, long-acting
β-agonists or tiotropium. The clinical, inflammatory and vi-
rologic data from the experimental rhinovirus infection
study have been reported in a previous publication [4].
At an initial screening visit potential subjects were
assessed for their suitability for the study. For those enter-
ing the study baseline clinical sampling was performed 1–
4 weeks prior to virus inoculation, which was on study
day 0. 10 TCID50 of the virus was diluted in a total volume
of 1 mL of 0.9% saline and inoculated in both nostrils.
Blood and sputum were collected at baseline prior to in-
fection, and on days 5, 9, 12, 15, 21, 28, 35 and 42 post-
inoculation. Sufficient samples for complete analyses were
collected from 10 smokers and 9 COPD subjects.
Symptom scores
Symptoms were assessed using diary cards that were
completed on a daily basis from screening until 6 weekspost-inoculation for the lower respiratory symptoms of
shortness of breath, cough, wheeze, sputum quantity
and sputum. The mean scores on days −6 to 0 were cal-
culated and subtracted from subsequent daily scores to
correct for baseline symptoms. In addition to the daily
scores symptom scores were calculated in 2-week blocks.
The baseline phase was the 2 weeks prior to infection
and the 2-week period from day 1 to day 14 was termed
the acute phase.
Inflammatory mediators
Total numbers of inflammatory cells and neutrophils were
counted in sputum samples and have been reported in
our previous publication [4]. A number of inflammatory
mediators including IL-6, IL-8, pentraxin and neutrophil
elastase were measured in sputum supernatants using
commercially available ELISAs and have been previously
reported [4,7]. Peripheral blood cell counts were measured
in the Clinical Haematology Laboratory of St Mary’s Hos-
pital, Imperial College Healthcare NHS Trust.
Isolation of neutrophils
Peripheral blood neutrophils were obtained according to
published methods. Briefly whole blood was collected,
layered onto a separation gradient (polymorphprep® Axis-
Shield), centrifuged, the neutrophil layer aspirated and
erythrocytes lysed. A sample of cells was stained with 0.1%
trypan blue for counting and assessment of viability, the
concentration adjusted to 4 × 106/mL, 100 μL of this sus-
pension added to the relevant antibodies, incubated at 4°C
for 45 minutes, fixed with 1% paraformaldehyde and
resuspended for analysis. Neutrophils prepared in this way
were >90% pure and >90% viable.
Sputum was induced according to European Respiratory
Society guidelines [8] and as previously described [4].
Subjects were pre-medicated with 200 μg salbutamol via
metered dose inhaler and large volume spacer and
baseline FEV1 measured. 4% saline was administered with
a DeVilbiss UltraNeb99 ultrasonic nebuliser until an
adequate sputum sample was obtained. Sputum was
processed within 2 hours of induction. Sputum plugs were
selected from saliva by macroscopic inspection of the
sample and 0.1% Dithiothreitol (DTT) added in the ratio
4 ml DTT to 1 g sputum and the mixture agitated and
filtered. The same volume PBS was added, the filtrate
centrifuged and the supernatant aliquotted and stored
at −80°C. The cell pellet was washed and resuspended and
the cells counted to obtain total cell counts. Cells were
then resuspended at 2 × 106/mL and antibody staining
performed as described for blood neutrophils.
Flow cytometry
All cells were stained with conjugated antibodies (BD
Pharmingen) and analyzed on a Fluorescence Activated
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settings were consistent throughout the study for each
subject. 20,000 events were counted for each sample of
blood neutrophils, and between 5000 and 20,000 events
for sputum neutrophils. Sputum cellular composition is
heterogeneous consisting predominantly of neutrophils
and monocyte/macrophages with smaller populations of
epithelial cells, eosinophils and lymphocytes, therefore
sputum required initial staining with CD14 (FITC) and
CD45 (QR) staining to identify neutrophils. A gate was
initially selected on size and granularity characteristics
and cells were then further characterised with CD14 and
CD45. Leukocytes were differentiated from cellular deb-
ris and epithelial cells by selecting CD45 (pan-leukocyte
marker) positive cells and neutrophils differentiated
from monocytes/macrophages by selecting CD14dim cells
[9,10]. This is described further in the Results section.
The adhesion molecules CD11a, CD11b, CD62L, CD162,
CD31, CD54 and the activation markers CD66b and
CD63 were detected using phycoerythrin (PE)-labelled
antibodies. PE-conjugated nonspecific antibodies of the
same isotype as the receptor antibodies were used as con-
trols to establish background fluorescence and nonspecific
antibody binding. The (arithmetic) mean fluorescence in-
tensity (MFI) of the cells stained with control antibody
was subtracted from the MFI of the receptor antibodies to
provide a measure of receptor-specific MFI. Cell surface
marker expression on neutrophils was analysed using
WinMDI 2. software.Statistical analysis
Data are presented as median (± interquartile range) and
changes from baseline were analysed with the Friedman
test. Differences between groups were analyzed by using
Mann–Whitney tests. Correlations between data sets
were examined using Spearman’s correlation. Differences
were considered significant for all statistical tests at P
values of less than 0.05 and all reported P values were
two-sided. Analysis was performed using GraphPad
Prism version 4.00 for Windows (GraphPad Software,
San Diego, USA).Results
Identification of neutrophils in sputum
Neutrophils in sputum were identified using CD14
and CD45 staining as described in the Methods
section. Representative plots of unstained cells show-
ing size and granularity characteristics are shown in
Figure 1A and 1C. Neutrophils were differentiated from
cellular debris, epithelial cells and monocytes/macro-
phages by selecting CD45 positive/CD14dim cells. Repre-
sentative plots of CD45/CD14 stained cells are shown in
Figure 1B and 1D.Neutrophil markers at baseline
Surface markers were initially measured on blood and
sputum neutrophils at baseline prior to rhinovirus infec-
tion in the stable state. No significant differences in ex-
pression of any marker were found between the groups
on either blood or sputum neutrophils (data not shown).
We next compared markers between blood and sputum
neutrophils to analyse the effect of neutrophil migration on
marker expression. Expression of CD11a, CD62L, CD31
and CD162 was significantly lower on sputum neutrophils
compared to blood neutrophils in both groups (Figure 2),
whereas CD11b and CD63 levels were significantly higher
on sputum neutrophils. Expression of the activation marker
CD66b was higher on sputum neutrophils in control sub-
jects, with a similar, but non-significant trend in the COPD
subjects (Figure 2H). There was no difference in CD54 ex-
pression between blood and sputum neutrophils in the con-
trols but expression was lower on sputum neutrophils
compared to blood in the COPD group.
Neutrophil markers following rhinovirus infection
Following rhinovirus infection there was no significant
change in expression of surface markers on sputum neutro-
phils (data not shown). On blood neutrophils expression of
CD11a, CD11b, CD62L and CD162 was reduced compared
to baseline values on days 5–12 post-inoculation, followed
by recovery to baseline levels. The nadir of marker expres-
sion from these 3 time points was chosen as the ‘infection’
time point and compared to baseline (pre-infection) and
convalescence (day 42) values. There was a significant fall in
CD11a expression at infection compared to baseline in both
groups (P < 0.05) (Figure 3A). Expression of CD11b, CD62L
and CD162 on blood neutrophils was significantly reduced
at infection compared to baseline in the COPD group but
not in the control subjects (Figure 3B-3D). There was a
trend towards increased expression of CD54 after infection
but this was not statistically significant. Expression of
CD31, CD63 and CD66 on blood neutrophils did not
change after infection in either group (data not shown).
Relationships between neutrophil markers and clinical
and inflammatory parameters
We analysed relationships between expression of neu-
trophil markers and clinical and inflammatory markers
following rhinovirus infection. In the COPD subjects
lower CD11b levels on blood neutrophils at infection were
associated with more symptoms, higher blood neutrophils
and higher levels of sputum neutrophil markers (Figure 4).
CD11b correlated inversely with cumulative 2 week acute
phase lower respiratory symptom scores (p = 0.021, r =−0.77),
cough scores (p = 0.0083, r = −0.83), peak blood neutro-
phils (p = 0.0053, r = −0.83) and sputum pentraxin (p =
0.031, r = −0.73) levels. There were trends towards correla-
tions with sputum neutrophil elastase (p = 0.05, r = −0.68),
Figure 1 Flow cytometry of sputum cells from 2 representative subjects. Panels A and C show representative plots of unstained sputum. A
gate was selected as shown to select for neutrophils on the basis of middle-range size and granularity. Panels B and D show these selected cells
stained with the markers CD45 (pan-leukocyte marker) and CD14 (monocyte/macrophage marker). The CD14low, CD45high cells (gate A) were
selected as representing neutrophils and analysed for expression of neutrophil markers. Monocytes/macrophages (CD14high, CD45high (gate B))
and epithelial cells (CD45low, CD14low cells (gate C)) were excluded.
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(p = 0.076, r = −0.63). There were no correlations in the
control subjects and there were no correlations between
any other neutrophil markers and clinical and inflamma-
tory parameters at infection.
Discussion
This is the first study to prospectively study neutrophil
adhesion molecules and activation markers in COPD
exacerbations. Following rhinovirus infection CD11b,
CD162 and CD62L levels were significantly reduced on
circulating neutrophils in COPD subjects, and CD11b
levels correlated with clinical and inflammatory parame-
ters at exacerbation. The results indicate a role for these
adhesion molecules in the recruitment of neutrophils to
the lungs in COPD exacerbations and may represent po-
tential therapeutic targets.
COPD exacerbations are associated with neutrophilic
inflammation [3,4], and neutrophil migration from theblood is mediated by adhesion molecules that are well
characterised in vitro but few studies have examined
their role in COPD exacerbations in vivo. Pharmaceut-
ical agents targeting these molecules are under develop-
ment as novel anti-inflammatory agents in asthma and
COPD [6], and therefore a better understanding of their
role in these diseases is required. We have previously
reported that experimental rhinovirus infection induces
increases in airway neutrophils in subjects with COPD
[4]. Following on from these observations we examined
expression of neutrophil adhesion molecules and activa-
tion markers in experimental rhinovirus infection in
COPD subjects and a control group of non-obstructed
smokers.
We initially examined neutrophil markers at baseline
prior to infection and there were no differences in expres-
sion in neutrophil markers between the groups. Previous
studies have reported increased CD162 [11], no differ-
ences in CD11a and CD62L [12-15] and both increased
Figure 2 Expression of neutrophil markers on blood and sputum neutrophils at baseline prior to infection in the COPD and control
groups. CD11a (Panel A), CD11b (Panel B), CD31 (Panel C), CD162 (Panel D), CD62L (Panel E), CD54 (Panel F), CD63 (Panel G), CD66b
(Panel H).* P < 0.05, **P < 0.01, ***P < 0.001.
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phils in COPD. These discrepant results are likely due to
variations between studies in severity of COPD, different
control groups and different methods of neutrophil isola-
tion. The COPD subjects in our study had moderate
COPD (GOLD stage II) and the comparator group were
similarly aged smokers without airway obstruction. There-
fore the exclusion of patients with severe COPD and the
choice of smokers as the comparator group may account
for the lack of differences between the groups. Comparing
marker expression on blood and sputum neutrophils wereport up-regulation of CD11b, CD63 and CD66 and
down-regulation of CD11a, CD31, CD162 and CD62L on
sputum neutrophils. Although CD11b is an adhesion mol-
ecule it is released from granules in neutrophils on activa-
tion and therefore unlike the other adhesion molecules it
is upregulated following neutrophil migration. Our results
are similar to those reported in allergy [18], asthma [19],
bronchiolitis [20] and sarcoidosis [10]. In COPD only
CD11b has been examined previously and increased ex-
pression on sputum neutrophils was reported [17]. CD162
is down-regulated upon neutrophil stimulation in vitro
Figure 3 Expression of adhesion molecules on blood neutrophils at baseline, during rhinovirus infection and at convalescence in
COPD subjects and non-obstructed smokers. CD11a (Panel A), CD11b (Panel B), CD162 (Panel C) and CD62L (Panel D). * P < 0.05 vs.
baseline, ** P < 0.01 vs. baseline.
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this is the first study to report down-regulation of CD162
following neutrophil migration to the lung in vivo. Follow-
ing rhinovirus infection there were no changes in neutro-
phil marker expression on sputum neutrophils. These
findings imply that changes in neutrophil surface markers
following migration from the blood to the lung are an ‘all
or nothing’ phenomenom and not specific to any particu-
lar disease process [10,18]. Therefore markers on sputum
neutrophils are unlikely to be helpful as diagnostic or
prognostic markers in airway diseases.
In contrast there were consistent changes in marker
expression on blood neutrophils following rhinovirus in-
fection. Only one study has examined neutrophil adhe-
sion molecules in COPD exacerbations and this study
reported reduced CD11a and CD11b but not CD62L on
blood neutrophils in exacerbated patients [12]. Studies
of neutrophils in virus infections have had conflicting re-
sults. Peripheral blood neutrophils collected during RSV
infections in infants showed no differences in CD11a,
CD11b or CD62L compared to controls [20]. In children
with viral wheeze CD62L was reduced but not CD11b
[23], and in adults with influenza infection CD11b was
increased [24]. These studies were all cross-sectional with
different subjects as controls, making interpretation of the
dynamics of neutrophil responses difficult. Our study is the
first to prospectively study marker expression within thesame subjects prior to and during the course of virus infec-
tions. We hypothesised that neutrophils expressing higher
levels of adhesion molecules would preferentially migrate
to the lungs following infection, and therefore the cells
remaining would consist of a population with lower surface
levels of adhesionmolecules. Following rhinovirus infection
CD11a on peripheral blood neutrophils was reduced in
both COPD and non-COPD subjects, and CD11b, CD62L
and CD162 were significantly reduced in COPD subjects
only. These data favour our hypothesis and suggest that
these adhesion molecules are key to neutrophil recruitment
to the lungs following virus infection in COPD. There was
no change in CD31, CD66b and CD63 expression on blood
neutrophils post-infection, consistent with their role in
endothelial transmigration and as neutrophil activation
markers respectively. There was a trend towards increased
CD54 expression on blood neutrophils post-infection. A
role of CD54 in neutrophil migration is unlikely, given our
current state of knowledge, as it has no known ligands on
endothelial cells, but it has been reported up-regulated on
peripheral blood neutrophils in RSV infection [20], follow-
ing exposure to endotoxin [25] and in sarcoidosis [10], and
therefore may be up-regulated in response to systemic
inflammation. Further studies are needed to determine
whether CD54 is upregulated in more severe exacerbations
or bacterial exacerbations and whether it plays a role in
neutrophil chemotaxis
Figure 4 Correlations between CD11b expression on blood neutrophils during rhinovirus infection with clinical and inflammatory
parameters in COPD subjects. Panel A. Two week aggregated lower respiratory symptoms scores. Panel B. Peak cough scores. Panel C. Peak
blood neutrophil counts. Panel D. Peak sputum pentraxin levels. Panel E. Peak sputum neutrophils. Panel F. Peak sputum neutrophil
elastase levels.
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CD11b expression on blood neutrophils in the COPD sub-
jects and respiratory symptoms and inflammatory markers.
Lower levels of bloodCD11b post-infection were associated
with more symptoms and greater neutrophilic inflamma-
tion in both blood and sputum. These data suggest that
CD11b is closely linked to virus-induced neutrophilic in-
flammation in COPD exacerbations and CD11b has poten-
tial as both a marker and therapeutic target in COPD
exacerbations. In an ozone-induced model of airway in-
flammation the CXCR2 antagonist SB-656933 inhibited
CXCL1-induced CD11b expression on peripheral blood
neutrophils and reduced neutrophilic inflammation in spu-
tum [26]. Our data suggests that this approach may also
have potential as a treatment for virus-induced COPD ex-
acerbations. Given our recent observation that secondarybacterial infections occurred in 60% of COPD subjects
following experimental rhinovirus infection, and that
virus-induced neutrophilic airway inflammation was im-
plicated in precipitating bacterial overgrowth via neu-
trophil elastase-mediated degradation of anti-microbial
peptides, therapeutic approaches that reduce neutrophil
migration and activation might have the attractive poten-
tial of preventing secondary bacterial infections [7].
Our study has a number of limitations that must be
considered when interpreting the results. The number of
subjects studied was relatively small and experimental
rhinovirus infection is limited to patients with moderate
COPD, and therefore may not be relevant to more
severe disease. Experimental infection studies will always
be limited by these factors but we believe that such stud-
ies are a useful tool to investigate mechanisms in COPD
Mallia et al. Respiratory Research 2013, 14:72 Page 8 of 9
http://respiratory-research.com/content/14/1/72exacerbations and generate hypotheses that warrant fur-
ther investigation in naturally-occurring exacerbations.
The surface markers we used to identify sputum neutro-
phils may not have excluded other cell types particularly
eosinophils. However eosinophils represented <2% of spu-
tum cells in these subjects and therefore are unlikely to
have had a major impact on the results [4]. Moreover the
results from the blood neutrophils are likely to be valid as
purified neutrophils were used.
In conclusion this is the first study to prospectively study
neutrophil marker expression in experimental rhinovirus
infection. We observed reduced expression of the adhesion
molecules CD11a, CD11b, CD62L and CD162 on peri-
pheral blood neutrophils following rhinovirus infection in
COPD subjects, and correlations between CD11b and ex-
acerbation severity. Further studies investigating the role of
adhesion molecules in other virus-induced disease such as
asthma exacerbations, and interventions targeting neutro-
phil adhesionmolecules are warranted.
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